Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice

Table 4 Other costs before and after starting the insulin treatment

	Pre-index		Post-index		Increment		Net cost effect
	Health care	Treatment	Health care	Treatment	Health care	Treatment	Net cost effect
Treatment	Mean/Median	Mean/Median	Mean/Median	Mean/Median	Mean/Median	Mean/Median	Mean/Median
NPH	25,417/9,215	5,209/2,445	24,173/10,439	6,287/2,926	−1,244/755	1,078/125	−166/880
IG	23,533/10,341	5,576/2,784	28,096/12,447	7,063/3,267	4,563/1,225	1,486/224	6,049/1,449
ID	20,297/9,205	4,515/1,455	22,313/10,652	5,300/1,819	2,016/1,717	785/160	2,801/1,877
PM	28,423/10,752	6,380/3,150	26,880/12,191	7,549/3,877	−1,543/883	1,169/283	−374/1,166
p-values	0.0054	<0.00001	0.0010	<0.00001	0.55	0.052

NPH Neutral protamine Hagedorn, IG insulin glargine, ID insulin determir, PM premixed insulin, SD standard deviation. The approximate value of 100 SEK is currently 12 US dollars (August 2015)

ISSN: 2055-8260